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Abstract: HtrA serine peptidase 2 (HtrA2), also named Omi, is a pro-apoptotic protein that exhibits
dramatic changes in expression levels in a variety of disorders, including ischemia/reperfusion injury,
cancer, and neurodegeneration. In our study, Omi/HtrA2 protein levels were high in the heart,
brain, kidney and liver, with elevated heart/brain expression in aging mice. A similar expression
pattern was observed at the mRNA level, which suggests that the regulation of Omi/HtrA2 is
predominately transcriptional. Promoter binding by transcription factors is the main influencing
factor of transcription, and to identify specific promoter elements that contribute to the differential
expression of mouse Omi/HtrA2, we constructed truncated Omi/HtrA2 promoter/luciferase reporter
vectors and analyzed their relative luciferase activity; it was greatest in the promoter regions at
´1205~´838 bp and ´146~+93 bp, with the ´838~´649 bp region exhibiting negative regulatory
activity. Bioinformatics analysis suggested that the Omi/HtrA2 gene promoter contains a CpG island
at ´709~+37 bp, and eight heat shock transcription factor 1 (HSF1) sites, two Sp1 transcription factor
(SP1)sites, one activator protein (AP) site, seven p53 sites, and four YY1 transcription factor(YY1)
sites were predicted in the core areas. Furthermore, we found that p53 and HSF1 specifically
binds to the Omi/HtrA2 promoter using chromatin immunoprecipitation analysis. These results
provide a foundation for understanding Omi/HtrA2 regulatory mechanisms, which could further
understanding of HtrA-associated diseases.
Keywords: Omi/HtrA2; promoter; transcriptional activity; luciferase

1. Introduction
Omi/HtrA2, a mitochondrial pro-apoptotic protein, is member of the High Temperature
Requirement (HtrA) family. Abnormal gene expression and localization of Omi/HtrA2 has been
associated with a variety of disease. For instance, Omi/HtrA2 expression is elevated in lung
adenocarcinoma [1], hepatocellular carcinoma [2,3], and squamous cell carcinoma of the head
and neck [4]. On the other hand, reduced expression has been observed in small lymphocytic
lymphoma/chronic lymphocytic leukemia (SLL/CLL) [5], testicular germ cell cancer [6] and ovarian
cancer [7–10]. Furthermore, overexpression of mature Omi/HtrA2, results in increased matrix
metallopeptidase 3 (MMP-3) activity and cell death in dopaminergic cells [11]. We previously reported
that overexpression of Omi/HtrA2 also contributes to apoptosis, and increases the susceptibility of
myocardial ischemia reperfusion injury in aging rat hearts [12,13]. All the above reports are consistent
with the possibility that alterations in Omi/HtrA2 transcription and protein levels are closely associated
Int. J. Mol. Sci. 2016, 17, 119; doi:10.3390/ijms17010119
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levels are closely associated with disease. Consequently, it is important to study the mechanisms of
with disease. Consequently, it is important to study the mechanisms of transcriptional regulation of
transcriptional regulation of Omi/HtrA2.
Omi/HtrA2.
Promoters, which are located upstream of genes, are key points for modulating transcriptional
Promoters, which are located upstream of genes, are key points for modulating transcriptional
levels. Gene promoters have many transcriptional binding sites, which can bind specific transcription
levels. Gene promoters have many transcriptional binding sites, which can bind specific transcription
factors and influence the mRNA expression levels and chromatin organization of the gene. CpG
factors and influence the mRNA expression levels and chromatin organization of the gene. CpG islands
islands are DNA sequences that are rich in CG nucleotides. They often are observed around the
are DNA sequences that are rich in CG nucleotides. They often are observed around the promoter
promoter region and the first exon of genes, where they are associated with major epigenetic
region and the first exon of genes, where they are associated with major epigenetic changes such as
changes such as methylation, which influences the expression of the associated genes. Therefore, it is
methylation, which influences the expression of the associated genes. Therefore, it is important to
important to consider both the transcription factor binding sites and the potential occurrence of CpG
consider both the transcription factor binding sites and the potential occurrence of CpG islands to
islands to obtain a multilevel understanding of the regulatory mechanism of genes.
obtain a multilevel understanding of the regulatory mechanism of genes.
In our study, we amplified the promoter of the mouse Omi/HtrA2 gene and analyzed its
In our study, we amplified the promoter of the mouse Omi/HtrA2 gene and analyzed its sequence
sequence using bioinformatics (Network Promoter Prediction, CpG Island Searcher, TFSEARCH,
using bioinformatics (Network Promoter Prediction, CpG Island Searcher, TFSEARCH, JAPAR,
JAPAR, PROMO). To study the core region of the promoter, we constructed an Omi/HtrA2
PROMO). To study the core region of the promoter, we constructed an Omi/HtrA2 promoter/luciferase
promoter/luciferase reporter vector, as well as several deletion mutants, which we transfected into
reporter vector, as well as several deletion mutants, which we transfected into murine fibroblast cells
murine fibroblast cells (NIH3T3), rat myocardial cells (H9c2) and human embryonic kidney cell
(NIH3T3), rat myocardial cells (H9c2) and human embryonic kidney cell (HEK-293) cells. This
(HEK-293) cells. This research provides a theoretical basis for study of the transcriptional regulation
research provides a theoretical basis for study of the transcriptional regulation and function of the
and function of the Omi/HtrA2 gene.
Omi/HtrA2 gene.
2.2. Results
Results
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To determine whether the differential expression of mouse Omi/HtrA2 is regulated at the level
of transcription, we assessed mRNA levels by QRT-PCR (Figure 1C). A similar pattern of high
To determine whether the differential expression of mouse Omi/HtrA2 is regulated at the
expression in the kidney and liver for young mice and the heart and brain for aging mice was
level of transcription, we assessed mRNA levels by QRT-PCR (Figure 1C). A similar pattern of
observed. These results verify the Western blotting results and suggest that the regulation of
high expression in the kidney and liver for young mice and the heart and brain for aging mice was
differential Omi/HtrA2 expression is likely to occur at the level of transcription and to involve a
observed. These results verify the Western blotting results and suggest that the regulation of differential
complex dynamic of regulatory factors.
Omi/HtrA2 expression is likely to occur at the level of transcription and to involve a complex dynamic
of
factors.
2.2.regulatory
Assessment
of the Activity of Mouse Omi/HtrA2 Promoter Luciferase Full-Length and Truncated Vectors
2.2. Assessment
of transcriptional
the Activity of Mouse
Omi/HtrA2
Luciferase Full-Length
and Truncated
Vectors
To analyze
activity
of the Promoter
mouse Omi/HtrA2
gene promoter,
we amplified
different lengths of the mouse Omi/HtrA2 gene promoter by PCR. Five products were amplified
To analyze transcriptional activity of the mouse Omi/HtrA2 gene promoter, we amplified different
using F1–F5 as upstream primers with R as a downstream primer (Table 1). The predicted products
lengths of the mouse Omi/HtrA2 gene promoter by PCR. Five products were amplified using F1–F5 as
were verified by 1% agarose gel electrophoresis (Figure S1) followed by sequencing. The five
upstream primers with R as a downstream primer (Table 1). The predicted products were verified by
truncated PCR products were cloned into PMD-18T, and then subcloned into the pGL3 luciferase
1% agarose gel electrophoresis (Figure S1) followed by sequencing. The five truncated PCR products
reporter vectors (pGL3). The resulting five luciferase reporter plasmids (named pGL3-239,
were cloned into PMD-18T, and then subcloned into the pGL3 luciferase reporter vectors (pGL3). The
pGL3-472, pGL3-742, pGL3-931, and pGL3-1298 according to length) were confirmed by KpnI and
resulting five luciferase reporter plasmids (named pGL3-239, pGL3-472, pGL3-742, pGL3-931, and
HindIII digest (Figure 2).
pGL3-1298 according to length) were confirmed by KpnI and HindIII digest (Figure 2).
Table 1. Primer sequences of different lengths of the mouse Omi/HtrA2 gene promoter. R is the
Table 1. Primer sequences of different lengths of the mouse Omi/HtrA2 gene promoter. R is the
shared reverse primer, and F1, F2, F3, F4 and F5 represent the forward primers for PCR fragments
shared reverse primer, and F1, F2, F3, F4 and F5 represent the forward primers for PCR fragments with
with different length.
different length.

Primer Name
Sequence (5’–3’)
Primer
Name
Sequence (5’–3’)
F1
AGAATTTCGAGGGCAGGGCTAA
AGAATTTCGAGGGCAGGGCTAA
F2 F1
CGTGAGGTGGCGATTAAG
CGTGAGGTGGCGATTAAG
F3 F2
TGGAAATAAGGACCCTGACG
F3
TGGAAATAAGGACCCTGACG
F4 F4
GTAGAGCAGTAGCGCGAGCA
GTAGAGCAGTAGCGCGAGCA
F5 F5
CTGGGAAGGCGGAGTCTTT
CTGGGAAGGCGGAGTCTTT
GGCAAGCGGTCTAGGAGAA
R R
GGCAAGCGGTCTAGGAGAA

Amplification Region (bp) Length (bp)
Amplification
Region (bp)
Length239
(bp)
−146~+93
´146~+93
239
−379~+93
472
´379~+93
472
−649~+93
742
´649~+93
742
−838~+93
931
´838~+93
931
−1205~+93
1298
´1205~+93
1298
––
––

Figure 2.
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4: pGL3-931;
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5:
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luciferase
expression
plasmids.
5: pGL3-1298. Luc: luciferase expression plasmids.

To identify the core regions of the mouse Omi/HtrA2 gene promoter, we transfected the
To identify the core regions of the mouse Omi/HtrA2 gene promoter, we transfected the luciferase
luciferase vector pGL3-basic (no insert) and the five truncated Omi/HtrA2 gene promoter luciferase
vector pGL3-basic (no insert) and the five truncated Omi/HtrA2 gene promoter luciferase plasmids
plasmids into NIH3T3, H9c2 and HEK-293 cells, with pRL renilla luciferase control reporter vector
into NIH3T3, H9c2 and HEK-293 cells, with pRL renilla luciferase control reporter vector (pRL-TK)
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(Table 3).
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shock transcription factor 1 (HSF1) sites, two SP1 sites, one AP site, seven p53 sites, four YY1 sites
(Table 3).
Table 2. Prediction of core area and CpG Island of Mouse Omi/HtrA2 promoter.
Prediction Area

Start

End

Promoter Sequence

Score
0.98

promoter core area 1

´1197

´1148

GAGGGCAGGGCTAAAAGTGGGCAGACAGG
AAAGGAACTAGGGCACCCACT

promoter core area 2

´359

´310

CCGGTGCGAGTCAAAGAGCCGCTCCGGC
CCCGGAGCTGGGGGAGGTTCCA

0.90

CpG island

´709

+37

Observed/Expected ratio > 0.60

Percent C + Percent G > 50.00

Table 3. Analysis of transcription factor binding sites of the Omi/HtrA2 promoter.
Transcription Factors

Number

Sequence of Putative Binding Sites

Location

HSF1

1
2
3
4
5
6
7
8

AAGGAACT
GTGGAAGC
CTTCTTGCTTTTTCT
ATGGAAGG
GGGGAACA
AGGGAAGA
ATGGAACC
CACAGAAT

+83~+90
´46~´39
´172~´158
´181~´174
´285~´278
´805~´798
´868~´861
´1028~´1021

SP1

1
2

GCCTCGCCCC
CACCCGCCTAT

´722~´713
´999~´899

AP1

1

CTATTGA

´944~´938

p53

1
2
3
4
5
6
7

CGTGCCC
GCGGCCC
GGGCTAG
GGGCATC
CCAGCCCAGCCC
GGGCTGG
GCAGCCC

+65~+71
´54~´48
´84~´78
´235~´229
´520~´509
´816~´810
´1103~´1197

YY1

1
2
3
4

GAAAAGACA
AGGGTGACA
CTGGGGACA
TGTCGCCGC

´867~´859
´843~´835
´551~´543
´177~´169

HSF1: Heat shock transcription factor 1; AP1:
YY1: YY1 transcription factor.

activator protein 1; SP1:

Sp1 transcription factor;

2.4. p53 and HSF1 Directly Binds to Omi/HtrA2 Promoter with ChIP Assay
To examined whether p53 or HSF1 binds to the Omi/HtrA2 promoter, ChIP assays were carried
out using mouse heart. We next reconfirmed the interaction of p53 or HSF1 with the Omi/HtrA2
promoter in vivo by ChIP assay. A p53 and HSF1 sense and antisense primer pair containing the p53
and HSF1 region showed a positive PCR signal in heart using anti-p53/HSF1 antibodies (Figure 4).
This result suggests that p53 and HSF1 can bind to Omi/HtrA2 promoter as transcriptional factors.
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Notably, bioinformatic predictions for the Omi/HtrA2 active regions were consistent with the
functional data obtained from luciferase assays. The RLA of pGL3-1298 (´1205~+93 bp) and pGL3-239
(´146~+93 bp) was significantly higher than pGL3-931 (´838~+93 bp) and pGL3-basic„ suggesting that
´1205~´838 bp and ´146~+93 bp comprise an active region of the Omi/HtrA2 promoter; consistently,
´1197~´1148 bp was predicted as an active region by bioinformatics analysis. The activity of pGL3-931
(´838~+93 bp) was lower than pGL3-742 (´649~+93 bp), suggesting that ´838~´649 bp region might
contain an inhibitory cis-acting element or constitute a CpG island.
The bioinformatics analysis using TFSEARCH, PROMO and JAPAR identified multiple
transcriptional binding sites on the Omi/HtrA2 promoter, including sites for HSF1, SP1, AP1, p53, and
YY1. The identification of the HSF1 binding sites has particular potential importance for Omi/HtrA2
regulation. HSF1 is a heat shock protein transcription factor, which is related to cell differentiation,
stress, aging and carcinogenesis. HSF1 is a master regulator of genes encoding molecular chaperones
and is involved in cellular processes such as the stress response, cellular differentiation, aging and
carcinogenesis. Suppression of HSF1 affects the advancement or maintenance of DNA damage
signaling-induced cell senescence [20]. The inactivation of HSF1 leads to remarkable reduction in
the transcript levels of its target genes, including heat shock protein family A (Hsp70) member 1A
(HSPA1A (Hsp70)), DnaJ heat shock protein family (Hsp40) member B1(DNAJB1 (Hsp40)), and heat
shock protein 90kDa alpha family class A member 1 (HSP90AA1) [21,22]. In C. elegans, HSF1 mediates
chaperone activity in muscle cells and neurons and is associated with aging [23].
The other binding sites identified within the Omi/HtrA2 promoter also have potential functional
significance. AP1 can induce myocardium apoptosis through the HO-1 pathway [24,25]. Decreased
expression of AP1 inhibits apoptosis in the aging brain [26]. HSF1 regulates jun proto-oncogene(JUN)
expression by binding to the JUN promoter, thereby modulating the activity of the transcriptional
activator protein 1 (AP1) [27]. Therefore, the occurrence of both HSF1 and AP1 sites within the
Omi/HtrA2 promoter could serve to amplify the regulatory effect. p53 modulates neuronal apoptosis,
partially by suppressing the anti-apoptotic protein X-linked inhibitor of apoptosis protein (XIAP) via
transcriptional activation of Omi/HtrA2 [28]. p53 induces activation of mitochondrial Omi/HtrA2
and blocks Ras-driven invasion by regulating the actin cytoskeleton [29]. YY1, histone deacetylase
3 (HDAC3) and histone deacetylase 4 (HDAC4) inhibit cell senescence by restraining p16 (INK4a)
expression through epigenetic modification of histones [30]. The combination of these different binding
sites within the Omi/HtrA2 promoter likely explains the complex pattern of tissue-specific expression.
HSF1 and p53 contain multiple predicted binding sites within the Omi/HtrA2 promoter, especially
in its core regions at ´1205~´838 bp and ´146~+93 bp, which may be the reason for the activity of
these regions. Furthermore, our study confirmed that HSF1 and p53 can bind to Omi/HtrA2 promoter
by ChIP assay, and are likely to be important transcriptional factors involved in regulating Omi/HtrA2
mRNA levels.
4. Materials and Methods
4.1. Animals
C57BL/6 male mice were purchased from Suzhou Ai Er Mai Te Technology Co., LTD (license No.:
SCXK [Su] 2014-0007) (Suzhou, China) and used at 6 months of age (“young”) or 24 months of age
(“aging”). All the animal experiments followed the Guiding Principles for the Use and Care of Animals
published by the National Institutes of Health (NIH publication no. 85-23, revised 1996).
4.2. Cell Lines and Cell Culture
NIH3T3, H9c2, and HEK293 cell lines were purchased from the Basic Medical Cell Center of
Peking Union Medical College (Beijing, China). H9c2 and HEK-293 cells were cultured in Dulbecco’s
modified Eagle’s medium (high glucose) with 10% fetal calf serum. NIH3T3 cells were grown in
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Dulbecco’s modified Eagle’s medium (high glucose) with 10% calf serum. The cells were cultured at
37 ˝ C and 5% CO2 .
4.3. Isolation of Genomic DNA
Genomic DNA was extracted from adult mouse hearts using the Universal Genomic DNA
Extraction Kit Ver. 3.0 (#DV811A; Takara, Dalian, China). The concentration and purity of DNA was
assessed using an ultramicro spectrophotometer (Implen GmbH, München, Germany). DNA samples
with OD260 /OD280 ratios of 1.8–2.0 were selected for subsequent experiments.
4.4. Design and Preparation of Mouse Omi/HtrA2 Gene Promoter Constructs
To prepare a full-length Omi/HtrA2 promoter luciferase constructs, we amplified a 1298 bp
fragment (´1205 to +93 bp), which includes the mouse Omi/HtrA2 gene promoter sequence, together
with the start site of the NCBI gene (MPRM17388, Genecopia, Rockville, MD, USA,). To prepare
promoter deletions, DNA fragments of different sizes were amplified using a shared reverse primer (R)
and 5 different forward PCR primers: F1, 239 bp (´146~+93 bp), F2, 472 bp (´379~+93 bp), F3, 742 bp
(´649~+93 bp), F4, 931 bp (´838~+93 bp), and F5, 1298 bp (´1205 ~+93 bp). The primer sequences are
shown in Table 1.
The DNA fragments were amplified using PrimeSTAR® HS DNA Polymerase (#DR010A; Takara)
in a 50 µL reaction mixture containing 10 µL 5ˆ PrimeSTAR Buffer (Mg2+ plus), 1 µL PrimeSTAR HS
DNA Polymerase (2.5 U/µL), 4 µL dNTP Mixture (2.5 mM each), 1 µL of each primer (10 µmol/L),
and 1 µL of DNA template (<1 µg). The PCR amplification protocol was as follows: denaturation at
94 ˝ C for 2 min; 35 cycles of denaturation at 95 ˝ C for 30 s, annealing at 62.4 ˝ C for 45 s, and extension
at 68 ˝ C for 30–90 s (according to the fragment length of PCR products, about 1 kb/1 min); and final
extension at 68 ˝ C for 10 min. Samples were stored at 4 ˝ C. All PCR products were verified by agarose
gel electrophoresis and sequencing.
PCR products were purified using a DNA gel extraction kit (#AP-GX-50; Axygen, Corning, NY,
USA), and then sticky end products were produced using a DNA A-Tailing Kit (Tiangen, Beijing,
China) with a 20 µL reaction mixture containing 15 µL purified PCR products, 4 µL A-Tailing Mix, and
1 µL A-Tailing Enzyme (2.5 U/µL). The reaction mixture was incubated at 72 ˝ C for 30 min and then
stored at 4 ˝ C. The A-tailing products were cloned into pMD18-T vector (#6011; Takara) to produce
recombinant constructs (pMD18-T-239 to pMD18-T-1298) which were confirmed by sequencing.
Recombinant constructs pMD18-T-239 to pMD18-T-1298 and pGL3 luciferase reporter vector
(#E1751; Promega, Madison, WI, USA) were digested for 4h at 37 ˝ C with KpnI (#1068A; Takara) and
HindIII (#1060A; Takara), and the fragments of the recombinant constructs were subcloned into pGL3.
The ligation mixtures, including 0.3 µg of recombinant fragments (KpnI/HindIII), 0.1 µg of pGL3-basic
plasmid (KpnI/HindIII), 1 µL of 10ˆ buffer M, and 1U of T4 ligase in a final volume of 10 µL, were
incubated at 16 ˝ C overnight and then 65 ˝ C for 5 min. The ligation mixtures were transformed into
E. coli DH5α cells. The positive recombinant clones (pGL3-239, pGL3-472, pGL3-742, pGL3-931, and
pGL3-1298; designated on the basis of their target fragment lengths) were extracted with a plasmid
mini kit (#AP-MN-P-50; Axygen) according to the manufacturer’s instructions. Recombinant plasmids
were verified by sequencing and double digestion with KpnI and HindIII.
4.5. Transfection and Luciferase Activity Assay
Cells were inoculated in 96-well plates at a density of 5 ˆ 104 cells/well and randomly divided into
7 groups: control (no transfection), pGL3-basic (no insert), pGL3-239, pGL3-472, pGL3-742, pGL3-931,
and pGL3-1298. The medium was aspirated and replaced with serum-free medium without antibiotics
4 h before transfection according to the protocol of Lipofectamine 2000 (#11668-027; Invitrogen,
Carlsbad, CA, USA). Lipofectamine 2000 (0.4 µL) was diluted with 25 µL Opti-MEM; and 100 ng of
plasmid encoding Firefly luciferase and 10 ng of internal control plasmid encoding Renilla luciferase
pRL-TK (#E2241; Promega) were diluted with 25 µL Opti-MEM® Reduced-Serum Medium (#31985;
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Gibco, Carlsbad, CA, USA). The mixtures were incubated for 20 min at room temperature and then
were added to the cells with antibiotic-free complete medium. Cell lysates were harvested 48 h
after transfection. Firefly luciferase and Renilla luciferase activity were tested using the Dual-Glo®
Luciferase Assay System (#E2920; Promega) according to the manufacturer’s instructions. Firefly and
Renilla luciferase activity were measured using a GloMax® 96 Microplate Luminometer (Promega,
Madison, WI, USA), and the relative luciferase activity (RLA) was determined by calculating their ratio.
4.6. Bioinformatics Analysis
In order to estimate the characteristic of the mouse Omi/HtrA2 promoter, bioinformatics analysis
was done using online tools. The core activity of the mouse Omi/HtrA2 promoter was predicted by
Network Promoter Prediction (Avalible online: http://www.fruitfly.org/seq_tools/promoter.html).
The CpG island of the mouse Omi/HtrA2 promoter was predicted by CpG Island Searcher
(Avalible online: http://cpgislands.usc.edu/) with lower limit values of the Observed/Expected
ratio > 0.60 and GC content >50%. Transcription factors and their binding sites in the
Omi/HtrA2 promoter were predicted by TFSEARCH (Avalible online: http://www.cbrc.jp/research/
db/TFSEARCH.html), JAPAR (Avalible online: http://jaspar.genereg.net/cgi-bin/jaspar_db.pl?rm=
browse&db=core&tax_group=vertebrates) and PROMO (Avalible online: http://alggen.lsi.upc.es/
cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3).
4.7. Western Blotting
Protein lysates from tissues were prepared as previously described [13], and protein concentrations
of lysates were determined using a BCA Protein Assay Kit (#23225; Thermo Scientific Pierce, Carlsbad,
CA, USA). Fifty µg/lane of each sample were run on 10% sodium dodecyl sulfatepolyacrylamide gel
electrophoresis (SDS-PAGE) gels, depending of the target proteins, and then were electrotransferred
onto polyvinylidene fluoride membranes. The membranes were incubated with primary antibodies
anti-Omi/HtrA2 (#2176; 1:1000; Cell Signaling Technology, Danvers, MA, USA) or rabbit
anti-glyceraldehyde-3-phosphate dehydrogenase/GAPDH (#2118; 1:1000; Cell Signaling Technology,
Danvers, MA, USA) overnight at 4 ˝ C, followed by incubation with the matched secondary antibodies
for 1h at room temperature. The density of the target protein bands was measured using ImageJ
software, and GAPDH was used as a protein loading control.
4.8. RNA Preparation and Quantitative Reverse Transcription-Polymerase Chain Reaction (QRT-PCR) Analysis
Total RNA was extracted from different tissues (heart, brain, liver, kidney, lungs, and spleen)
in adult and aging mouse hearts using the RNAprep pure Tissue Kit (#DP431; Tiangen). The
first cDNA strand was synthesized using a 1st-Strand cDNA Synthesis Kit (RR036A; Takara), and
then real time PCR was performed using the SYBR PrimeScript RT-PCR Kit (RR820A; Takara).
All of the procedures were performed according to the manufacturer’s instructions. Primers of
mouse Omi/HtrA2 and GAPDH for QRT-PCR (SYBR) were designed and synthesized as follow:
GAPDH-F: 5’-CTCTCTGCTCCTCCCTGTTCC-3’; GAPDH-R, 5’-CGTTCACACCGACCTTCACC-3’;
Omi-F, 5’-ATCTCCTTTGCCATCCCTTC-3’; Omi-R, 5’-GGTCAGCATCATCACTCCAA-3’. The
expression of Omi/HtrA2 mRNA in different tissues was calculated by the 2´∆∆Ct method, with
GAPDH as internal control.
4.9. ChIP Assay
The ChIP assay was performed according to the instructions of the Magna ChIP G Tissue Kit
(#17-20000; millipore EZ-ChIP, Darmstadt, Germany). Briefly, mouse heart were treated with 1% (w/v)
formaldehyde for 15 min. Cross-linked chromatin was then prepared and sonicated to an average size
of 500 bp. DNA fragments were immunoprecipitated with antibodies specific to HSF1 (#4356; Cell
Signaling Technology, Danvers, MA, USA), p53 (#ab28; Abcam, Cambridge, UK), or control rabbit,
mouse IgG at 4 ˝ C overnight. After reversal of cross-linking, the immunoprecipitated chromatin
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was amplified by primers corresponding to core regions of the Omi/HtrA2 promoter. Primers
were designed and synthesized as follow: Omi promoter-F, 5’-GCTACCGTCGTGCCCTGCTT-3’;
Omi promoter-R, 5’-ATGCCCGAAGGCTCCAGTTT-3’.
4.10. Statistical Analysis
All values in the text and figures are expressed as mean ˘ SD. Significant differences between
two transfection group were subjected to ANOVA and followed by post-hoc Dunn’s multiple
comparison test. Western blot densities and QRT-PCR were analyzed using the Kruskal–Wallis
test followed by Dunn’s post hoc test.
5. Conclusions
The tissue-specific expression of Omi/HtrA2 and its changing trend in aging mice was
demonstrated in our study. The Omi/HtrA2 promoter’s active region was mapped from ´1205
to ´838 bp and ´146 to +93 bp, with the ´838 to ´649 bp region exhibiting negative regulatory
activity according to bioinformatics analysis and a dual-luciferase reporter assay system. A CpG
island was predicted at ´709 to +37 bp of the Omi/HtrA2 promoter. On the basis of these findings,
the Omi/HtrA2 promoter may be methylated and include transcriptional binding sites (HSF1, SP1,
AP1, p53, and YY1). HSF1 and p53 can bind to Omi/HtrA2 promoter, and are likely to be important
transcriptional factors in regulating Omi/HtrA2 mRNA levels.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
17/1/119/s1.
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